ReviewJournal of inorganic biochemistry2011
Towards the prevention of potential aluminum toxic effects and an effective treatment for Alzheimer's disease.
Review in Journal of inorganic biochemistry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts.Critical reviews in toxicology · 2014Pooled it
- A Water-soluble Turn-on Fluorescent Probe of Aluminum Ions Based On Quinoline Derivative and Its Implication for the Detection of 2,4,6-Trinitrophenol.Journal of fluorescence · 2026Article
- Co-exposure to Aluminium and Cadmium Mediates Postpartum Maternal Variation in Brain Architecture and Behaviour of Mice; Involvement of Oxido-nitrergic and Cholinergic Mechanisms : Postpartum effects of Aluminium and Cadmium co-exposure in pregnancy.Biological trace element research · 2025Article
- Intranasal delivery of iron chelators and management of central nervous system disease.Frontiers in pharmacology · 2025Review
- Long-Term Temporospatial Complementary Relationship between Degradation and Bone Regeneration of Mg-Al Alloy.ACS applied bio materials · 2023Article
- Review
- Early insight into the potential contribution of aluminum to neurodegeneration - A tribute to the research work of Robert D. Terry, Igor Klatzo, Henryk M. Wisniewski and Donald R.C. Mclachlan.Journal of inorganic biochemistry · 2020Article
- Is heart disease a risk factor for low dementia test battery scores in older persons with Down syndrome? Exploratory, pilot study, and commentary.International journal of developmental disabilities · 2020Article
- Gut Microbiota Disorder, Gut Epithelial and Blood-Brain Barrier Dysfunctions in Etiopathogenesis of Dementia: Molecular Mechanisms and Signaling Pathways.Neuromolecular medicine · 2019Review
- Aluminum Exposure from Parenteral Nutrition: Early Bile Canaliculus Changes of the Hepatocyte.Nutrients · 2018Article
- Effect of PGEOncotarget · 2017Article
- Recent Findings in Alzheimer Disease and Nutrition Focusing on Epigenetics.Advances in nutrition (Bethesda, Md.) · 2016Review
- Beta-Amyloid Precursor Protein (βAPP) Processing in Alzheimer's Disease (AD) and Age-Related Macular Degeneration (AMD).Molecular neurobiology · 2015Review
- Trace elements in scalp hair samples from patients with relapsing-remitting multiple sclerosis.PloS one · 2015Article
- Aluminium involvement in neurotoxicity.BioMed research international · 2014Article
- Aluminum and its potential contribution to Alzheimer's disease (AD).Frontiers in aging neuroscience · 2014Article
- In vitro biocompatibility assessment of Ti40Cu38Zr10Pd12 bulk metallic glass.Journal of materials science. Materials in medicine · 2014Article
- Expression of the phagocytosis-essential protein TREM2 is down-regulated by an aluminum-induced miRNA-34a in a murine microglial cell line.Journal of inorganic biochemistry · 2013Article
- Deferoxamine: emerging, new neuro-protective benefits.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Article
- Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD).Expert opinion on emerging drugs · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
In 1991, treatment with low dose intramuscular desferrioxamine (DFO), a trivalent chelator that can remove excessive iron and/or aluminum from the body, was reported to slow the progression of Alzheimer's disease (AD) by a factor of two. Twenty years later this promising trial has not been followed up and why this treatment worked still is not clear. In this critical interdisciplinary review, we provide an overview of the complexities of AD and involvement of metal ions, and revisit the neglected DFO trial. We discuss research done by us and others that is helping to explain involvement of metal ion catalyzed production of reactive oxygen species in the pathogenesis of AD, and emerging strategies for inhibition of metal-ion toxicity. Highlighted are insights to be considered in the quests to prevent potentially toxic effects of aluminum toxicity and prevention and intervention in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.